Pacific Biomarkers leverages the Aushon Cira platform to attain unprecedented Range of Quantitation (RoQ), accuracy, and precision on a panel of biomarkers related to angiogenesis.
Presented by Jeff Chamberlain, Ph.D., and Andrew Macintyre, M.D., Ph.D.
Development of Highly Sensitive Clinical PK Assays
Presented by Andrew Macintyre M.D., Ph.D.and Sarah Christensen B.S.
Pacific Biomarkers will now provide enhanced clinical laboratory services to researchers analyzing biomarkers using the Cira platform.
PBI will provide access to its extensive menu of validated biomarker assays to support WuXi PharmaTech, a leading pharmaceutical company in Shanghai, with integrated clinical trial testing services.
Pacific Biomarkers announces the expansion of its services portfolio to include ultra-sensitive biomarker assays using the Singulex Erenna Immunoassay technology.
The Pacific Biomarkers-Clinigene partnership combines biomarker support for clinical trial research of the former with development capabilities of ligandbinding assays of the latter in a cost-effective business model situated in India.